Terlipressin: Physiology and What Research Reports

What terlipressin is

Terlipressin is a synthetic analogue of vasopressin (antidiuretic hormone), a nine–amino-acid peptide hormone. Structurally it is a triglycyl derivative of lysine-vasopressin, which behaves as a slow-release precursor: tissue peptidases progressively cleave the glycyl residues, liberating the active vasoconstrictor over a longer interval than native vasopressin. A 2023 drug profile described terlipressin as a vasopressin analogue developed for the prevention and treatment of renal decline in hepatorenal syndrome, acting with relative preference for V1 receptors on vascular smooth muscle (PMID 37873544).

Because it is a modified natural peptide rather than a small molecule, terlipressin is frequently encountered in peptide literature as an example of how backbone extension can change a hormone's duration of action and receptor selectivity. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or treatment decision.

Where the parent hormone comes from and what it does

Native vasopressin is synthesised by magnocellular neurons of the hypothalamic paraventricular and supraoptic nuclei, transported down axons to the posterior pituitary, and released into the circulation in response to rising plasma osmolality or falling effective blood volume. Two receptor families dominate its physiology:

• V1a receptors on vascular smooth muscle, especially in the splanchnic circulation, mediating vasoconstriction.
• V2 receptors in the renal collecting duct, mediating aquaporin-mediated water reabsorption.

Terlipressin's research interest follows from that split. Reviews of hepatorenal syndrome described the disorder as arising from splanchnic arterial vasodilation in advanced cirrhosis, with a fall in effective arterial blood volume and consequent renal vasoconstriction, and positioned terlipressin as a splanchnic vasoconstrictor intended to correct that circulatory pattern alongside albumin (PMID 38353275). The residual V2 activity is the mechanistic explanation usually offered for the free-water retention and hyponatraemia described in case reports (PMID 20302535).

How terlipressin is measured and studied

Terlipressin is not assayed in routine practice the way an endogenous hormone is. Instead, published studies tracked physiological surrogates and clinical endpoints. Across the hepatorenal syndrome literature, researchers used serum creatinine change, reversal of hepatorenal syndrome (creatinine returning below a defined threshold), need for renal replacement therapy, mean arterial pressure, transplant-free survival and mortality. A 2024 review summarised how these endpoints have been defined and applied in the terlipressin evidence base (PMID 38353275).

What the literature reports

Placebo-controlled trial evidence

The CONFIRM trial, published in 2021, randomised patients with type 1 hepatorenal syndrome to terlipressin plus albumin or placebo plus albumin, with terlipressin given intravenously at 1 mg every 6 hours, and the researchers reported that verified reversal of hepatorenal syndrome occurred significantly more often in the terlipressin group than in the placebo group (PMID 33657294). The same trial reported that adverse events were more frequent with terlipressin, with respiratory failure and deaths attributed to respiratory disorders occurring more often in the terlipressin arm (PMID 33657294).

Continuous infusion versus intermittent boluses

A 2016 randomised controlled study compared terlipressin given by continuous intravenous infusion with intermittent intravenous boluses in hepatorenal syndrome, and the researchers reported that adverse events were less frequent with continuous infusion while the mean effective daily dose was lower, with comparable rates of response between the two administration strategies (PMID 26659927). A 2025 phase 2 trial of a continuous-infusion terlipressin formulation (BIV201) examined safety and efficacy in patients with decompensated cirrhosis and refractory ascites, extending the infusion concept beyond hepatorenal syndrome (PMID 40272365).

Subgroups and real-world series

A 2025 analysis examined terlipressin for hepatorenal syndrome in patients with early-stage acute-on-chronic liver failure, a group in which the balance of renal response and organ-failure risk has been debated (PMID 41200852). The HRS Harmony Consortium described United States experience with terlipressin, reporting on response rates, mortality and transplant outcomes outside the controlled-trial setting (PMID 42107856).

Terlipressin Adverse Events: What Studies Report

The adverse-event literature is dominated by consequences of vasoconstriction, by water retention, and by cardiac effects. Case reports capture the extreme end of the spectrum, while pooled trial analyses describe frequency across larger populations.

Case reports describe individual events and cannot establish how often an event occurs; pooled trial analyses such as the 2025 arrhythmia review provide frequency estimates within the populations that were enrolled (PMID 40704461).

Why the term matters to peptide readers

Terlipressin is a useful teaching case for three reasons. First, it shows how a peptide can be engineered as a precursor whose slow enzymatic cleavage functions as built-in extended release, a design principle discussed in its 2023 drug profile (PMID 37873544). Second, it illustrates that receptor selectivity is relative, not absolute: the same molecule that produces intended splanchnic vasoconstriction has been linked in reports to hyponatraemia through V2 activity (PMID 20302535). Third, it demonstrates how route and schedule can change a tolerability profile without a different molecule, as reported in the infusion-versus-bolus comparison (PMID 26659927).

Limitations of the evidence

• Most controlled data come from hospitalised patients with advanced cirrhosis and acute kidney injury, a narrow and severely ill population.
• Several safety signals rest on single case reports, which describe association rather than incidence.
• Endpoint definitions for hepatorenal syndrome have shifted over time, complicating comparison across studies, as discussed in the 2024 review (PMID 38353275).
• Terlipressin is a prescription hospital agent studied under monitoring; the cited literature contains no data on use outside supervised clinical settings.

References

• Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome (The New England Journal of Medicine, 2021)
• Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study (Hepatology, 2016)
• Safety and efficacy of continuous infusion terlipressin (BIV201): A phase 2 trial in patients with decompensated cirrhosis and refractory ascites (Liver Transplantation, 2025)
• Terlipressin for Hepatorenal Syndrome in Patients With Early-Stage Acute-on-Chronic Liver Failure (Liver International, 2025)
• United States Experience With Terlipressin in Hepatorenal Syndrome: Response, Mortality, and Transplant Outcomes - Results From the HRS Harmony Consortium (Clinical Gastroenterology and Hepatology, 2026)
• Terlipressin for hepatorenal syndrome (Current Opinion in Gastroenterology, 2024)
• Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug Profile (Gastroenterology Insights, 2023)
• Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies (Alimentary Pharmacology & Therapeutics, 2025)
• Terlipressin-Associated Complete Heart Block (ACG Case Reports Journal, 2025)
• Terlipressin-induced foot ischemia (Clinical Case Reports, 2021)
• Terlipressin-induced ischaemic skin necrosis (BMJ Case Reports, 2020)
• Terlipressin-induced hyponatremic seizure (Scandinavian Journal of Gastroenterology, 2010)